Insmed, Inc. $INSM Shares Acquired by Vanguard Group Inc.

Vanguard Group Inc. raised its position in shares of Insmed, Inc. (NASDAQ:INSM) by 13.0% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 19,935,820 shares of the biopharmaceutical company’s stock after purchasing an additional 2,291,328 shares during the quarter. Vanguard Group Inc. owned about 0.09% of Insmed worth $2,870,957,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. Stone House Investment Management LLC bought a new stake in shares of Insmed in the 3rd quarter worth approximately $29,000. SBI Securities Co. Ltd. raised its holdings in Insmed by 404.9% during the third quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 166 shares in the last quarter. MassMutual Private Wealth & Trust FSB lifted its holdings in shares of Insmed by 59.6% in the third quarter. MassMutual Private Wealth & Trust FSB now owns 217 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 81 shares during the period. Whittier Trust Co. of Nevada Inc. lifted its holdings in Insmed by 169.7% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 240 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 151 shares during the last quarter. Finally, AlphaQuest LLC boosted its holdings in Insmed by 109.5% during the third quarter. AlphaQuest LLC now owns 287 shares of the biopharmaceutical company’s stock worth $41,000 after buying an additional 150 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on INSM. Wolfe Research set a $167.00 price target on Insmed and gave the stock an “outperform” rating in a research note on Thursday, December 18th. Mizuho set a $212.00 target price on Insmed in a report on Thursday, December 18th. Citigroup reaffirmed an “outperform” rating on shares of Insmed in a research report on Thursday, December 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Insmed in a research report on Thursday, January 22nd. Finally, Bank of America set a $203.00 price objective on Insmed in a research report on Thursday, December 18th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Insmed presently has an average rating of “Buy” and an average price target of $204.24.

Insider Activity

In related news, Director Elizabeth M. Anderson sold 5,000 shares of the firm’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $204.58, for a total value of $1,022,900.00. Following the transaction, the director owned 58,729 shares in the company, valued at $12,014,778.82. This trade represents a 7.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Orlov S. Nicole Schaeffer sold 87,290 shares of the firm’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $175.20, for a total value of $15,293,208.00. Following the completion of the transaction, the insider owned 41,754 shares in the company, valued at $7,315,300.80. This represents a 67.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 173,253 shares of company stock worth $29,629,842. Insiders own 3.00% of the company’s stock.

Insmed Price Performance

Shares of INSM stock opened at $151.11 on Thursday. The company has a market capitalization of $32.23 billion, a P/E ratio of -24.41 and a beta of 1.11. The company has a current ratio of 4.63, a quick ratio of 4.34 and a debt-to-equity ratio of 0.59. The stock has a 50 day moving average of $166.45 and a two-hundred day moving average of $162.80. Insmed, Inc. has a 12 month low of $60.40 and a 12 month high of $212.75.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.